Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Major Depressive Disorder-Pipeline Review, H1 2015

Major Depressive Disorder-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Major Depressive Disorder-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Major Depressive Disorder-Pipeline Review, H1 2015', provides an overview of the Major Depressive Disorder's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Major Depressive Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Major Depressive Disorder and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Major Depressive Disorder

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Major Depressive Disorder and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Major Depressive Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Major Depressive Disorder pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Major Depressive Disorder

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Major Depressive Disorder pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Major Depressive Disorder Overview 8

Therapeutics Development 9

Pipeline Products for Major Depressive Disorder-Overview 9

Pipeline Products for Major Depressive Disorder-Comparative Analysis 10

Major Depressive Disorder-Therapeutics under Development by Companies 11

Major Depressive Disorder-Therapeutics under Investigation by Universities/Institutes 15

Major Depressive Disorder-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Unknown Stage Products 19

Major Depressive Disorder-Products under Development by Companies 20

Major Depressive Disorder-Products under Investigation by Universities/Institutes 24

Major Depressive Disorder-Companies Involved in Therapeutics Development 25

Actavis plc 25

Alkermes Plc 26

Angelini Group 27

Azevan Pharmaceuticals, Inc. 28

BioCrea GmbH 29

Bristol-Myers Squibb Company 30

Cerecor Inc. 31

e-Therapeutics plc 32

Edgemont Pharmaceuticals, LLC 33

Eli Lilly and Company 34

Euthymics Bioscience, Inc. 35

F. Hoffmann-La Roche Ltd. 36

GlaxoSmithKline plc 37

H. Lundbeck A/S 38

Hua Medicine Ltd. 39

Intas Pharmaceuticals Ltd. 40

Intra-Cellular Therapies, Inc. 41

Jiangsu Hansoh Pharmaceutical Co., Ltd. 42

Johnson & Johnson 43

Lead Discovery Center GmbH 44

Luye Pharma Group Ltd. 45

Methylation Sciences Inc. 46

miCure Therapeutics Ltd. 47

Mitsubishi Tanabe Pharma Corporation 48

Naurex, Inc. 49

Neuralstem, Inc. 50

nLife Therapeutics, S.L. 51

Otsuka Holdings Co., Ltd. 52

Pherin Pharmaceuticals, Inc. 53

Reviva Pharmaceuticals Inc. 54

Richter Gedeon Nyrt. 55

Saniona AB 56

Sumitomo Dainippon Pharma Co., Ltd. 57

Sunovion Pharmaceuticals Inc. 58

Suven Life Sciences Ltd. 59

Trevena, Inc. 60

VistaGen Therapeutics , Inc. 61

Major Depressive Disorder-Therapeutics Assessment 62

Assessment by Monotherapy Products 62

Assessment by Combination Products 63

Assessment by Target 64

Assessment by Mechanism of Action 67

Assessment by Route of Administration 70

Assessment by Molecule Type 72

Drug Profiles 74

(aripiprazole + sertraline)-Drug Profile 74

(samidorphan + buprenorphine hydrochloride)-Drug Profile 75

amitifadine-Drug Profile 77

AN-788-Drug Profile 79

aripiprazole-Drug Profile 80

AV-101-Drug Profile 81

AVP-786-Drug Profile 83

basimglurant-Drug Profile 85

brexpiprazole-Drug Profile 87

bupropion hydrochloride ER-Drug Profile 89

cariprazine-Drug Profile 90

CERC-301-Drug Profile 92

desvenlafaxine succinate SR-Drug Profile 93

EDG-005-Drug Profile 94

edivoxetine-Drug Profile 95

esketamine hydrochloride-Drug Profile 97

INASTR-001-Drug Profile 99

ITI-007-Drug Profile 100

lurasidone hydrochloride-Drug Profile 102

LY-03005-Drug Profile 104

LY-2940094-Drug Profile 105

MIN-117-Drug Profile 106

miR-135-Drug Profile 107

MSI-195-Drug Profile 108

NLF-NEU-Drug Profile 109

NRX-1074-Drug Profile 110

NSI-189-Drug Profile 111

onabotulinumtoxin A-Drug Profile 112

PH-10-Drug Profile 114

rapastinel-Drug Profile 115

RP-5063-Drug Profile 117

SEP-363856-Drug Profile 118

Small Molecule to Inhibit FKBP51 for Major Depressive Disorder-Drug Profile 119

Small Molecule to Target SLC6A15 for Major Depressive Disorder-Drug Profile 120

Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders-Drug Profile 121

Small Molecules to Antagonize NMDA Receptor 2B for Depression and Major Depressive Disorder-Drug Profile 122

Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System-Drug Profile 123

Small Molecules to Antagonize NR2B for Major Depression-Drug Profile 124

Small Molecules to Inhibit COMT for Cognitive Disorders-Drug Profile 125

SRX-246-Drug Profile 126

SUVN-911-Drug Profile 128

tedatioxetine-Drug Profile 129

tramadol hydrochloride-Drug Profile 131

trazodone hydrochloride-Drug Profile 133

TRV-250-Drug Profile 134

vortioxetine hydrobromide-Drug Profile 135

Major Depressive Disorder-Recent Pipeline Updates 138

Major Depressive Disorder-Dormant Projects 178

Major Depressive Disorder-Discontinued Products 184

Major Depressive Disorder-Product Development Milestones 187

Featured News & Press Releases 187

Appendix 196

Methodology 196

Coverage 196

Secondary Research 196

Primary Research 196

Expert Panel Validation 196

Contact Us 196

Disclaimer 197

List of Tables

Number of Products under Development for Major Depressive Disorder, H1 2015 13

Number of Products under Development for Major Depressive Disorder-Comparative Analysis, H1 2015 14

Number of Products under Development by Companies, H1 2015 16

Number of Products under Development by Companies, H1 2015 (Contd..1) 17

Number of Products under Development by Companies, H1 2015 (Contd..2) 18

Number of Products under Investigation by Universities/Institutes, H1 2015 19

Comparative Analysis by Late Stage Development, H1 2015 20

Comparative Analysis by Clinical Stage Development, H1 2015 21

Comparative Analysis by Early Stage Development, H1 2015 22

Comparative Analysis by Unknown Stage Development, H1 2015 23

Products under Development by Companies, H1 2015 24

Products under Development by Companies, H1 2015 (Contd..1) 25

Products under Development by Companies, H1 2015 (Contd..2) 26

Products under Development by Companies, H1 2015 (Contd..3) 27

Products under Investigation by Universities/Institutes, H1 2015 28

Major Depressive Disorder-Pipeline by Actavis plc, H1 2015 29

Major Depressive Disorder-Pipeline by Alkermes Plc, H1 2015 30

Major Depressive Disorder-Pipeline by Angelini Group, H1 2015 31

Major Depressive Disorder-Pipeline by Azevan Pharmaceuticals, Inc., H1 2015 32

Major Depressive Disorder-Pipeline by BioCrea GmbH, H1 2015 33

Major Depressive Disorder-Pipeline by Bristol-Myers Squibb Company, H1 2015 34

Major Depressive Disorder-Pipeline by Cerecor Inc., H1 2015 35

Major Depressive Disorder-Pipeline by e-Therapeutics plc, H1 2015 36

Major Depressive Disorder-Pipeline by Edgemont Pharmaceuticals, LLC, H1 2015 37

Major Depressive Disorder-Pipeline by Eli Lilly and Company, H1 2015 38

Major Depressive Disorder-Pipeline by Euthymics Bioscience, Inc., H1 2015 39

Major Depressive Disorder-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 40

Major Depressive Disorder-Pipeline by GlaxoSmithKline plc, H1 2015 41

Major Depressive Disorder-Pipeline by H. Lundbeck A/S, H1 2015 42

Major Depressive Disorder-Pipeline by Hua Medicine Ltd., H1 2015 43

Major Depressive Disorder-Pipeline by Intas Pharmaceuticals Ltd., H1 2015 44

Major Depressive Disorder-Pipeline by Intra-Cellular Therapies, Inc., H1 2015 45

Major Depressive Disorder-Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H1 2015 46

Major Depressive Disorder-Pipeline by Johnson & Johnson, H1 2015 47

Major Depressive Disorder-Pipeline by Lead Discovery Center GmbH, H1 2015 48

Major Depressive Disorder-Pipeline by Luye Pharma Group Ltd., H1 2015 49

Major Depressive Disorder-Pipeline by Methylation Sciences Inc., H1 2015 50

Major Depressive Disorder-Pipeline by miCure Therapeutics Ltd., H1 2015 51

Major Depressive Disorder-Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015 52

Major Depressive Disorder-Pipeline by Naurex, Inc., H1 2015 53

Major Depressive Disorder-Pipeline by Neuralstem, Inc., H1 2015 54

Major Depressive Disorder-Pipeline by nLife Therapeutics, S.L., H1 2015 55

Major Depressive Disorder-Pipeline by Otsuka Holdings Co., Ltd., H1 2015 56

Major Depressive Disorder-Pipeline by Pherin Pharmaceuticals, Inc., H1 2015 57

Major Depressive Disorder-Pipeline by Reviva Pharmaceuticals Inc., H1 2015 58

Major Depressive Disorder-Pipeline by Richter Gedeon Nyrt., H1 2015 59

Major Depressive Disorder-Pipeline by Saniona AB, H1 2015 60

Major Depressive Disorder-Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 61

Major Depressive Disorder-Pipeline by Sunovion Pharmaceuticals Inc., H1 2015 62

Major Depressive Disorder-Pipeline by Suven Life Sciences Ltd., H1 2015 63

Major Depressive Disorder-Pipeline by Trevena, Inc., H1 2015 64

Major Depressive Disorder-Pipeline by VistaGen Therapeutics , Inc., H1 2015 65

Assessment by Monotherapy Products, H1 2015 66

Assessment by Combination Products, H1 2015 67

Number of Products by Stage and Target, H1 2015 69

Number of Products by Stage and Mechanism of Action, H1 2015 72

Number of Products by Stage and Route of Administration, H1 2015 75

Number of Products by Stage and Molecule Type, H1 2015 77

Major Depressive Disorder Therapeutics-Recent Pipeline Updates, H1 2015 142

Major Depressive Disorder-Dormant Projects, H1 2015 182

Major Depressive Disorder-Dormant Projects (Contd..1), H1 2015 183

Major Depressive Disorder-Dormant Projects (Contd..2), H1 2015 184

Major Depressive Disorder-Dormant Projects (Contd..3), H1 2015 185

Major Depressive Disorder-Dormant Projects (Contd..4), H1 2015 186

Major Depressive Disorder-Dormant Projects (Contd..5), H1 2015 187

Major Depressive Disorder-Discontinued Products, H1 2015 188

Major Depressive Disorder-Discontinued Products (Contd..1), H1 2015 189

Major Depressive Disorder-Discontinued Products (Contd..2), H1 2015 190

List of Figures

Number of Products under Development for Major Depressive Disorder, H1 2015 13

Number of Products under Development for Major Depressive Disorder-Comparative Analysis, H1 2015 14

Number of Products under Development by Companies, H1 2015 15

Comparative Analysis by Late Stage Development, H1 2015 20

Comparative Analysis by Clinical Stage Development, H1 2015 21

Comparative Analysis by Early Stage Products, H1 2015 22

Assessment by Monotherapy Products, H1 2015 66

Number of Products by Top 10 Targets, H1 2015 68

Number of Products by Stage and Top 10 Targets, H1 2015 69

Number of Products by Top 10 Mechanism of Actions, H1 2015 71

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 72

Number of Products by Top 10 Routes of Administration, H1 2015 74

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 75

Number of Products by Top 10 Molecule Types, H1 2015 76

Number of Products by Stage and Top 10 Molecule Types, H1 2015 76

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Actavis plc

Alkermes Plc

Angelini Group

Azevan Pharmaceuticals, Inc.

BioCrea GmbH

Bristol-Myers Squibb Company

Cerecor Inc.

e-Therapeutics plc

Edgemont Pharmaceuticals, LLC

Eli Lilly and Company

Euthymics Bioscience, Inc.

F. Hoffmann-La Roche Ltd.

GlaxoSmithKline plc

H. Lundbeck A/S

Hua Medicine Ltd.

Intas Pharmaceuticals Ltd.

Intra-Cellular Therapies, Inc.

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Johnson & Johnson

Lead Discovery Center GmbH

Luye Pharma Group Ltd.

Methylation Sciences Inc.

miCure Therapeutics Ltd.

Mitsubishi Tanabe Pharma Corporation

Naurex, Inc.

Neuralstem, Inc.

nLife Therapeutics, S.L.

Otsuka Holdings Co., Ltd.

Pherin Pharmaceuticals, Inc.

Reviva Pharmaceuticals Inc.

Richter Gedeon Nyrt.

Saniona AB

Sumitomo Dainippon Pharma Co., Ltd.

Sunovion Pharmaceuticals Inc.

Suven Life Sciences Ltd.

Trevena, Inc.

VistaGen Therapeutics , Inc.

Major Depressive Disorder Therapeutic Products under Development, Key Players in Major Depressive Disorder Therapeutics, Major Depressive Disorder Pipeline Overview, Major Depressive Disorder Pipeline, Major Depressive Disorder Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com